These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 7786309

  • 1. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.
    Marder P, Sawyer JS, Froelich LL, Mann LL, Spaethe SM.
    Biochem Pharmacol; 1995 May 26; 49(11):1683-90. PubMed ID: 7786309
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT, Froelich LL, Boyd RJ, Schrementi JP, Saussy DL, Schultz RM, Sawyer JS, Sofia MJ, Herron DK, Goodson T, Snyder DW, Pechous PA, Spaethe SM, Roman CR, Fleisch JH.
    J Pharmacol Exp Ther; 1999 Jan 26; 288(1):286-94. PubMed ID: 9862783
    [Abstract] [Full Text] [Related]

  • 3. Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.
    Sawyer JS, Bach NJ, Baker SR, Baldwin RF, Borromeo PS, Cockerham SL, Fleisch JH, Floreancig P, Froelich LL, Jackson WT.
    J Med Chem; 1995 Oct 27; 38(22):4411-32. PubMed ID: 7473568
    [Abstract] [Full Text] [Related]

  • 4. Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events.
    Fretland DJ, Anglin CP, Bremer M, Isakson P, Widomski DL, Paulson SK, Docter SH, Djuric SW, Penning TD, Yu S.
    Inflammation; 1995 Apr 27; 19(2):193-205. PubMed ID: 7601505
    [Abstract] [Full Text] [Related]

  • 5. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111).
    van Pelt JP, de Jong EM, van Erp PE, Mitchell MI, Marder P, Spaethe SM, van Hooijdonk CA, Kuijpers AL, van de Kerkhof PC.
    Biochem Pharmacol; 1997 Apr 04; 53(7):1005-12. PubMed ID: 9174114
    [Abstract] [Full Text] [Related]

  • 6. Leukotriene B4-induced granulocyte trafficking in guinea pig dermis. Effect of second-generation leukotriene B4 receptor antagonists, SC-50605 and SC-51146.
    Fretland DJ, Widomski DL, Anglin CP, Penning TD, Yu S, Djuric SW.
    Inflammation; 1993 Jun 04; 17(3):353-60. PubMed ID: 8392493
    [Abstract] [Full Text] [Related]

  • 7. Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production.
    Schultz RM, Marder P, Spaethe SM, Herron DK, Sofia MJ.
    Prostaglandins Leukot Essent Fatty Acids; 1991 Aug 04; 43(4):267-71. PubMed ID: 1658812
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions.
    Tsai BS, Villani-Price D, Keith RH, Zemaitis JM, Bauer RF, Leonard R, Djuric SW, Shone RL.
    Prostaglandins; 1989 Dec 04; 38(6):655-74. PubMed ID: 2561214
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Multiple actions of the leukotriene B4 receptor antagonist SC-41930.
    Villani-Price D, Yang DC, Walsh RE, Fretland DJ, Keith RH, Kocan G, Kachur JF, Gaginella TS, Tsai BS.
    J Pharmacol Exp Ther; 1992 Jan 04; 260(1):187-91. PubMed ID: 1309871
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.
    Sarau HM, Foley JJ, Schmidt DB, Martin LD, Webb EF, Tzimas MN, Breton JJ, Chabot-Fletcher M, Underwood DC, Hay DW, Kingsbury WD, Chambers PA, Pendrak I, Jakas DR, Sathe GM, Van Horn S, Daines RA, Griswold DE.
    Prostaglandins Leukot Essent Fatty Acids; 1999 Jul 04; 61(1):55-64. PubMed ID: 10477044
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The leukotriene B4 receptor agonist/antagonist activities of SC-45694 in human neutrophils.
    Tsai BS, Keith RH, Villani-Price D, Haack RA, Djuric SW.
    J Pharmacol Exp Ther; 1994 Mar 04; 268(3):1493-8. PubMed ID: 8138959
    [Abstract] [Full Text] [Related]

  • 16. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696.
    Showell HJ, Pettipher ER, Cheng JB, Breslow R, Conklyn MJ, Farrell CA, Hingorani GP, Salter ED, Hackman BC, Wimberly DJ.
    J Pharmacol Exp Ther; 1995 Apr 04; 273(1):176-84. PubMed ID: 7714764
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
    Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M.
    Leukemia; 2005 Nov 04; 19(11):1977-84. PubMed ID: 16151469
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. SC-41930, a leukotriene B4 receptor antagonist, inhibits 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) binding to epidermal cells.
    Kemény L, Ruzicka T.
    Agents Actions; 1991 Mar 04; 32(3-4):339-42. PubMed ID: 1650525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.